| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17408 R73020 |
Madley-Dowd_SE (Gabapentin) (Controls exposed to LTG) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes Partial overlapping |
1.18 [0.74;1.87] excluded (control group) |
21/864 134/5,035 | 155 | 864 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17411 R73038 |
Madley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 0.97 [0.64;1.50] | 21/864 68,788/2,651,210 | 68,809 | 864 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17410 R73032 |
Madley-Dowd_SE (Gabapentin) (Controls unexposed, sibling) (Mixed indications), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes Partial overlapping |
0.59 [0.24;1.43] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17281 R72384 |
Madley-Dowd_UK (Gabapentin) (Controls exposed to LTG) (Mixed indications), 2024 | Autism - ICD10 codes - Median 4.93 (3.11-7.46) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.30 [0.66;2.58] excluded (control group) |
16/564 20/939 | 36 | 564 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17265 R72385 |
Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 | Autism - ICD10 codes - Median 4.93 (3.11-7.46) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.43 [0.88;2.32] | 16/564 7,657/514,066 | 7,673 | 564 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17273 R72386 |
Madley-Dowd_UK (Gabapentin) (Controls unexposed, sibling) (Mixed indications), 2024 | Autism - ICD10 codes - Median 4.93 (3.11-7.46) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes |
0.97 [0.41;2.25] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12760 R48899 |
Bjørk (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up gabapentin 3.5 (1.7-6.7) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.80 [0.39;1.66] C excluded (control group) |
8/965 82/7,950 | 90 | 965 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12761 R48900 |
Bjørk (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up gabapentin 3.5 (1.7-6.7) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
0.94 [0.47;1.88] excluded (control group) |
8/965 38,437/4,463,879 | 38,445 | 965 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12762 R48901 |
Bjørk (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up gabapentin 3.5 (1.7-6.7) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 0.67 [0.33;1.36] C | 8/965 267/21,634 | 275 | 965 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10095 R46667 |
Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.80 [0.40;7.00] excluded (control group) |
3/378 11/2,916 | 14 | 378 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8517 R46668 |
Coste (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 2.30 [0.80;7.30] | 3/378 4,280/1,710,441 | 4,283 | 378 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8499 R46670 |
Wood, 2015 | Score >30 (CARS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 17.00 [0.13;2166.90] C | 0/1 0/9 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.14 [0.76;1.70] | 81,040 | 2,772 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Gabapentin) (Controls unexposed, general pop) (Mixed indications; 2: Gabapentin) (Controls unexposed, general pop) (Mixed indications; 3: Controls unexposed, sick) (Mixed indications; 4: Controls unexposed, NOS) (Mixed indications;
Asymetry test p-value = 0.3949 (by Egger's regression)
slope=-0.2129 (0.3698); intercept=1.1417 (1.1524); t=0.9907; p=0.3949
excluded 10095, 12760, 12761, 17408, 17410, 17281, 17273